IOPtima Will Commence Selling an Innovative System for Glaucoma Surgeries in Israel

BioLight announced today that its subsidiary, IOPtima (87.17%), has signed an exclusive distribution agreement with Tradis Gat, one of the leading importers and marketers of medical products in Israel, within the framework of which Tradis Gat has committed to purchase at least 8 IOPtimate™ systems for performing a unique surgery for the treatment of Glaucoma disease.

Link to the complete article

Link to Newsroom

Comments are closed.